Claims

1. Use of a composition comprising menotropin in the manufacture of a medicament for the treatment of infertility in a patient to thereby promote the development of euploid blastocysts for future blastocyst transfer, the treatment comprising:

identifying a patient having a serum antimullerian hormone (AMH) level ≥ 5.2 ± 0.5 ng/ml and an antral follicle count (AFC) ≥ 10 in both ovaries combined prior to treatment/stimulation; and

administering a dose of, or a dose equivalent to, 75 to 300 IU hMG per day from day 1 to at least day 5 of treatment.

2. Use according to claim 1 wherein the treatment to promote the development of euploid blastocysts for future blastocyst transfer increases the proportion/percentage of euploid blastocysts compared to the proportion/percentage of aneuploid blastocysts and/or reduces aneuploidy rate.

3. Use according to any preceding claim wherein the treatment further comprises: administering hCG to trigger ovulation.

4. Use according to any preceding claim wherein the treatment further comprises:
retrieving (e.g. harvesting) oocyte(s);
fertilizing (e.g. inseminating) the oocytes (s); and
allowing the fertilized oocytes to develop to the blastocyst stage.

5. Use according to claim 4 wherein the treatment further comprises assessing the chromosomal quality of blastocyst(s) obtained after fertilization of the harvested oocytes.

6. Use according to claim 5 wherein the treatment further comprises transfer of a euploid blastocyst identified by assessment of chromosomal quality of the blastocyst(s); or freezing a euploid blastocyst identified by assessment of chromosomal quality of the blastocyst(s).

7. Use according to any preceding claim wherein the menotropin is highly purified menotropin (HP-hMG).

8. Use according to any preceding claim wherein the treatment comprises a step of administration to the patient a dose of, or a dose equivalent to, 75 to 200 IU HP-hMG per day from day 1 to at least day 5 of treatment.

9. Use according to any preceding claim wherein the treatment comprises a step of administration to the patient a dose of, or dose equivalent to, 150 IU HP-hMG per day from day 1 to at least day 5 of treatment.

10. Use according to any preceding claim, comprising a further step of administering a GnRH antagonist on day 6 of treatment.